Skip to main content

Table 2 Total HPV-attributable cancer cost (€) in specialist care according to cancer diagnosis, 2014, € 1.00 = NOK 8.357

From: The healthcare costs of treating human papillomavirus-related cancers in Norway

Cancer diagnosis HPV-related total costs (€) Base Case Analysis (Hansen et al. 2015) [15] Sensitivity Analysis (Saraiya et al. 2015) [16]
Proportion attributable to HPV (%) HPV-attributable total costs (€) Proportion attributable to HPV (%) HPV-attributable costs (€)
Cervical cancer 17,213,190 100 17,213,190 90.6 15,595,150
Vaginal cancer 462,786 81 374,857 75 347,090
Vulvar cancer 3,395,240 29 984,620 68.8 2,335,925
Penile cancer 1,623,327 47 762,964 63.3 1,027,566
Anal cancer 5,108,420 90 4,597,578 90.6a 4,628,229
Oropharyngeal cancer 11,736,770 57 6,689,959 67.85a 7,963,398
Total burden of HPV 39,539,733   30,623,167   31,897,358
Proportion of HPV-related total cost (%)    77.45   80.67
  1. aAverage HPV-attributable proportion. Originally reported as gender specific rates in Saraya et al. 88.7% (male) and 92.6% (female) for anal cancer and 63.3% (female) and 72.4% (male) for oropharyngeal cancer